

PharMerica CORP  
Form 8-K  
May 07, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 7, 2015**

**PHARMERICA CORPORATION**

**(Exact Name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**1901 Campus Place**

**001-33380**  
**(Commission**  
**File Number)**

**87-0792558**  
**(IRS Employer**  
**Identification No.)**

**40299**

**Louisville, Kentucky**  
**(Address of principal executive offices)**  
**(502) 627-7000**

**(Zip Code)**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On May 7, 2015, PharMerica Corporation (the Company ) issued a press release announcing results of operations for the first quarter ended March 31, 2015, a copy of which is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release of PharMerica Corporation dated May 7, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PHARMERICA CORPORATION**

Date: May 7, 2015

By: /s/ David W. Froesel, Jr.  
David W. Froesel, Jr.  
Executive Vice President, Chief Financial Officer  
and Treasurer

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of PharMerica Corporation dated May 7, 2015.